Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation
- PMID: 37030981
- DOI: 10.1016/j.cpet.2023.02.007
Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation
Abstract
Fibroblast activation protein (FAP)-targeted radioligand therapy offers a possibility of a novel cancer therapeutic strategy, aiming at tumor stroma1. Early clinical translations of FAP-tracers occurred as early as in the 1990s using antibodies, without substantial achievement further than the clinical phase II trial. The essential step toward the theranostic approach, with a conceptual combination of diagnostic and therapeutic emitters in a specific tracer, began with the implementation of small-molecule FAP-enzyme inhibitors (FAPI) in 2018. Currently, FAPI-04 and FAPI-46, containing DOTA-chelators with the possibility of radionuclide combination (Ga-68, Y-90, and Lu-177), are the compounds most widely used in the theranostic regimen.
Keywords: Clinical translation; FAPI; Fibroblast; Radioligand therapy; Theranostic.
Copyright © 2023 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
